It is defined as proportion of patients who had progressed at or before 9 months after randomization, i.e., the time from the randomization to the date when the first observation of disease progression (earliest of the date when the first CA 125 meets progression definition and the date of first objective relapse or progression, defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions, recorded) has been documented o
Group
Value
95% CI
Arm 1
0.386
Arm 2
0.347
Arm 3
0.245
Progression Free SurvivalSecondary· During the study with median follow-up of 33 months
Time from the day of randomization until the time when first observation of disease progression (earliest of the dates of first CA125 which meets progression definition and first objective relapse or progression defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions, has been documented or when death due to any cause has been observed.
Group
Value
95% CI
IV Carboplatin + IV Paclitaxel
11.3
8.8 – 14.7
IP Cisplatin + IV/IP Paclitaxel
12.7
9.7 – 18.0
IP Carboplatin + IV/IP Paclitaxel
12.5
10.8 – 15.0
Overall SurvivalSecondary· During the study with median follow-up of 33 months
Time from the day of randomization to death from any cause.
Group
Value
95% CI
IV Carboplatin + IV Paclitaxel
38.1
32.9 – 47.7
IP Cisplatin + IV/IP Paclitaxel
40.6
38.7 – 68.1
IP Carboplatin + IV/IP Paclitaxel
59.3
34.2 – 68.3
Adverse events — posted to ClinicalTrials.gov
Time frame: During the time when patients were treated by protocol therapy, up to 9 months.
Reporting threshold: 5%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
RATIONALE: Drugs used in chemotherapy, such as paclitaxel, carboplatin, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) and giving them in different ways may kill more tumor cells. It is not yet known which combination chemotherapy regimen is more effective in treating patients with ovarian epithelial cancer, primary peritoneal cancer, and fallopian tube cancer.
PURPOSE: This randomized phase II trial is comparing the side effects of three combination chemotherapy regimens and to see how well they work in treating patients with stage IIB, stage IIC, stage III, or stage IV ovarian epithelial cancer, primary peritoneal cancer, or fallopian tube cancer.
Publications & conference data
4 peer-reviewed publications reference this trial (live from Europe PMC):
NCT07405190 — Ivonescimab Alone And With Carboplatin/Pemetrexed For NSCLC
· Phase 2
· not yet recruiting
NCT07527806 — Optimization of Dynamic Neoadjuvant Therapy Strategies for HER2-Positive Breast Cancer Based on HER2-PET/CT Molecular Im
· Phase 2
· not yet recruiting
NCT07498907 — Disitamab Vedotin Plus Radiotherapy for Adjuvant Treatment of HER2-Expressing Cisplatin-Ineligible Upper Tract Urothelia
· Phase 2
· not yet recruiting
NCT06694454 — Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immun
· Phase 1, PHASE2
· not yet recruiting
NCT07472517 — DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carbop
· Phase 3
· not yet recruiting
Other recruiting trials for Fallopian Tube Cancer
Currently open trials in the same condition.
NCT07402915 — Drug-drug Interaction Study With AZD5335 and Itraconazole in Participants With Ovarian, Primary Peritoneal, or Fallopian
· Phase 1
· recruiting
NCT06915025 — Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemo
· Phase 3
· recruiting
NCT06787612 — Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
· Phase 2
· recruiting
NCT07023484 — Personalized Timing of Interval Debulking Surgery in Advanced Ovarian Cancer
· Phase 2
· recruiting
NCT07460180 — The PROOV Study: Exploiting the Synergistic Effect of PARP Inhibition With Cisplatin and Hyperthermia During Interval Cy
· Phase 1, PHASE2
· recruiting
Other Canadian Cancer Trials Group trials
Trials by the same sponsor.
NCT07390435 — Feasibility and Acceptability of Collecting Sociodemographic Data in CCTG Trials
· not yet recruiting
NCT07297667 — GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid Tumours
· Phase 1
· not yet recruiting
NCT06630273 — Canadian Initiative to Measure, Predict and Assess Cancer Treatment Outcomes in Patients Treated With Immuno-Oncotherape
· not yet recruiting
NCT07152821 — Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcino
· Phase 3
· recruiting
NCT07341191 — Sonrotoclax Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma Planned for Standard of Care CAR
· Phase 2
· not yet recruiting
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Canadian Cancer Trials Group
Last refreshed: 28 August 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00993655.